The FDA picked the LP.8.1 Covid strain for the fall vaccines, fueling concerns that the shots may be limited to only the most ...

In view of the recent surge in COVID-19 cases in various parts of the country, the Delhi government has issued an advisory ...

Low uptake may reflect barriers—misinformation, access or shifting insurance coverage—not simply waning need.

FDA's new COVID-19 vaccine policy may restrict low-risk individuals' access, pending clinical trials to prove benefits.

The FDA will limit the vaccine’s availability later this year to older adults and those who may be at risk of severe illness.

Despite the fact that vaccines against COVID have already undergone strict safety reviews and that people continue to die ...

The Trump administration released a 72-page report Thursday outlining its take on what's driving "a chronic disease crisis" ...

Vaccine advisers to the FDA decided Thursday that only strains of the JN.1 variant should be targeted by updated versions of covid vaccines that will be available next fall and winter. Separately, ...

The advisory committee meeting comes days after the FDA unveiled a new risk-based approval framework for COVID-19 vaccines.

The “Make America Healthy Again” report calls for increased scrutiny of the childhood vaccine schedule, a review of the ...

At the outset of the meeting, the FDA's new top vaccine regulator, Vinay Prasad, said he and FDA leaders wanted to "give people a little more time to digest the policy." He said that the FDA is still ...

Secretary Kennedy's appointment led to fears that vaccine availability would be curtailed. Those fears are now being realized.